Medication-assisted treatment has become a part of treatment modalities that are combined with counseling and behavioral therapies to provide all-inclusive approach to treating substance use disorders. The medication-assisted treatment market has witnessed its use in alcohol and opioid use disorders. Growing traction of evidence-based treatment options among healthcare providers has been driving the evolution of the market.
In recent years, a number of medications are used for treating opioid use disorder, a worldwide problem. Some of the medications used to treat opioid use disorders (OUD) have been associated by stigma, since they are heavily regulated by agencies, such as the FDA.
The WHO has been promoting the adoption of medication-assisted treatment to end the opioid crisis. The market has been witnessing the demand for such medications for inpatient and outpatient facilities. Key product types in the medication-assisted treatment market are buprenorphine, methadone, and naltrexone. Key end users include rehabilitation clinic, hospital, and home care setting.
The medication-assisted treatment (MAT) market has been witnessing rise in acceptance of such medications in drug abuse habits. MAT has become integral part of practicing counselling and therapies, and in many cases being preferred over treatment methods. Opioid overdose prevention medications are growing in popularity. Prevention of opioid overdose is becoming a mounting concern for healthcare providers. Methadone in its liquid form is growing in demand in the medication-assisted treatment market. Patient providers are increasingly benefitting from the range of treatments that can be used for opioid use disorders (OUD). The variety of MAT medications expand the options for patient populations, and hence is imperative.
Growing trend of combining MAT in counseling and psychosocial support is fueling the prospects in the medication-assisted treatment (MAT) market. Over the years, the support has moved from hospital setting to home care settings. Growing number of people in the U.S. who struggle with opioid use disorders and drug abuse disorders has spurred the opportunity generation for drug makers in the market.
The MAT market has seen regulatory agencies continually making efforts need for continuing MAT should be re?evaluated periodically. For instance, FDA regularly updates in finalizing new policies to development of new buprenorphine treatments for opioid use disorders. Drug makers in the MAT market has also benefitted from public meeting on patient-focused drug development for opioid use disorder. The growing approval of non-opioid treatments for opioid withdrawal symptoms especially in adults has boosted the growth of the medication-assisted treatment market. Due to high out-of-pocket expenditure for MAT, payers are accepting open models.
Some of the key industry stakeholders in the medication-assisted treatment market are Rosemont Pharmaceuticals Limited, Titan Pharmaceuticals, Inc, Teva Pharmaceuticals, and BioDelivery Sciences International, Inc.
Some of the key regional markets are Europe, North America, East Asia, South Asia, Latin America, and Middle East and Africa. Of these, North America has occupied a high share in the MAT market. Government and healthcare professionals are accepting MAT as a part of treatment modality. Europe is also a promisingly lucrative regional market. These regions are expected to see new revenue streams on the back of the increased focus of governments and healthcare providers to address the drug abuse and opioid use disorders. Regional agencies are also focusing on ensuring MAT medications and child safety. Healthcare providers in the U.S. are promoting the use of behavioral therapies. A case in point is the designing training and resources by Substance Abuse and Mental Health Services Administration